37LBA Telotristat etiprate is effective in treating patients with carcinoid syndrome that is inadequately controlled by somatostatin analog therapy (the phase 3 TELESTAR clinical trial)

Matthew H. Kulke,Dieter Hörsch,Martyn Caplin,Lowell B. Anthony,Emily K. Bergsland,Kjell Öberg,Staffan Welin,Richard R.P. Warner,Catherine Lombard-Bohas,Pamela L. Kunz,Enrique Grande,Juan W. Valle,Douglas Fleming,Pablo Lapuerta,Phillip Banks,Shanna Jackson,Darren Wheeler,Brian Zambrowicz,Arthur T. Sands,M. Pavel

37LBA Telotristat etiprate is effective in treating patients with carcinoid syndrome that is inadequately controlled by somatostatin analog therapy (the phase 3 TELESTAR clinical trial)

2015

Telotristat etiprate is effective in treating patients with carcinoid syndrome that is inadequately controlled by somatostatin analog therapy (the phase 3 TELESTAR clinical trial)

Keywords:

Clinical trial
Somatostatin Analog Therapy
Pathology
Internal medicine
Telotristat Etiprate
Intensive care medicine
Carcinoid syndrome
Medicine
Diabetes mellitus

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations